Relating to the controlled substance schedules and to clean-up errors identified in the code sections
HB3434 is a controlled-substances housekeeping bill that amends and reenacts West Virginia’s drug scheduling statutes in §60A-2-204, §60A-2-206, §60A-2-208, §60A-2-210, and §60A-2-212. The bill updates the state’s Schedule I through Schedule V lists to reflect current controlled substances, including numerous fentanyl analogs, synthetic cannabinoids, synthetic cathinones, benzodiazepines, stimulants, opioids, hallucinogens, and other emerging drugs. It also includes language clarifying that fentanyl and carfentanil remain Schedule II substances, and it preserves existing exceptions for certain lawful products, such as hemp/cannabis products authorized elsewhere in state law and FDA-approved medications in specified forms.
The measure is described in the caption as addressing “clean-up errors identified in the code sections,” indicating that part of its purpose is technical correction and modernization of the controlled-substances code rather than a major policy overhaul. In practical terms, it keeps West Virginia’s controlled substance schedules aligned with current drug trends and federal/state enforcement needs, while also clarifying which substances are covered under each schedule and which products remain exempt. The bill takes effect 90 days from passage, on July 10, 2025.
The overall sentiment reflected in the voting history was strongly supportive. The House passed the bill by a wide margin after rejecting one amendment, and the Senate passed it unanimously. That pattern suggests broad bipartisan agreement that the state needed to update and clean up its controlled-substances schedules, likely to aid law enforcement and reduce ambiguity in enforcement and prosecution.
The main point of contention appears to have been the rejected House amendment, which failed 20-71, though no transcript is available to show the substance of the amendment or the arguments for and against it. Because the bill is largely a technical update to drug schedules, opposition seems limited and may have centered on the scope of scheduling, the inclusion of specific substances, or concerns about overbreadth in classifying emerging compounds. However, the final votes indicate that any disagreement was not enough to prevent enactment.
HB3434 amends West Virginia Code §60A-2-204, §60A-2-206, §60A-2-208, §60A-2-210, and §60A-2-212, which govern the state’s controlled substance schedules. It updates the statutory lists of Schedule I through Schedule V substances, adds or clarifies coverage for many synthetic drugs and analogs, and makes technical corrections to existing code language. The bill affects law enforcement, prosecutors, regulated medical and pharmaceutical products, and anyone manufacturing, possessing, distributing, or prescribing substances listed in the schedules.
The bill appears to have been received positively overall, with strong bipartisan support in both chambers. The House passed it 89-3 after defeating an amendment, and the Senate passed it 32-0. That voting pattern suggests broad agreement that the scheduling updates and code clean-up were necessary and noncontroversial at the final stage.
The only visible contention in the available record is the House amendment that was rejected 20-71 on March 26, 2025. Because there are no committee transcripts, the specific issue is unknown, but it likely involved either the scope of substances being scheduled or the technical details of the update. Aside from that amendment, the bill’s final passage was not closely contested, and the Senate vote was unanimous.